Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria") ...

Sterotherapeutics, a leading biopharmaceutical company dedicated to advancing innovative therapies, is announcing the launch of a Phase 2 clinical trial for ST-002, a novel drug candidate for patients ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...

Actinogen Medical Ltd (ASX:ACW) said its net loss after tax for the six months to December 2024 decreased by 29% to ...

COURTESY UH CANCER CENTER The Queen’s Health Systems and University of Hawaii Cancer Center will develop an oncology clinic at the UH John A. Burns School of Medicine in Kakaako. 1 /3 COURTESY UH ...

Objective This study aimed to investigate the incidence of overweight in patients with major depressive disorder (MDD) comorbid anxiety during the acute phase and to explore associated factors. Design ...

Researchers’ understanding of the pathogenesis of rheumatoid arthritis has grown considerably in recent years, laying the ...

If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...

The patch-delivered vaccine trial received $28.5m in funding from US authorities as a potential pandemic preparation.